Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KRAS G12C-mutant non-small-cell lung cancer, drawn from the whole corpus: 38 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Responses to G12C inhibitors are shallower and shorter in lung cancer than EGFR or ALK inhibitors achieve, and no overall survival benefit over docetaxel has been shown.
Liver toxicity when a G12C inhibitor follows or accompanies a checkpoint inhibitor limits first-line combinations.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
STK11 and KEAP1 co-mutations predict poor outcome with every treatment and have no targeted therapy.
Background: RAS / RAF / MEK / ERK (MAPK). Also on OnCo: Targets · KRAS roadmap.
Resistance is polyclonal and mechanistically diverse, arguing for combinations from the start.
Nothing recorded yet.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance atlas · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).
KRAS G12C NSCLC after ≥1 line; 5 Jan 2024 (conditional)
PFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.